Previous close | 234.90 |
Open | 234.20 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 233.20 - 236.80 |
52-week range | 233.20 - 317.40 |
Volume | |
Avg. volume | 9,031 |
Market cap | 2.002B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 0.14 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.